PMC:7324763 / 41220-41342 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T562","span":{"begin":117,"end":119},"obj":"Body_part"}],"attributes":[{"id":"A562","pred":"fma_id","subj":"T562","obj":"http://purl.org/sig/ont/fma/fma86578"}],"text":"Anti-PD-1 (pembrolizumab) + tocilizumab NCT04335305 II Nanjing, China 24 Pneumatic COVID19+ Tocilizumab = anti-IL-6R"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T306","span":{"begin":88,"end":95},"obj":"Disease"}],"attributes":[{"id":"A306","pred":"mondo_id","subj":"T306","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Anti-PD-1 (pembrolizumab) + tocilizumab NCT04335305 II Nanjing, China 24 Pneumatic COVID19+ Tocilizumab = anti-IL-6R"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T168","span":{"begin":5,"end":7},"obj":"Chemical"},{"id":"T169","span":{"begin":28,"end":39},"obj":"Chemical"},{"id":"T170","span":{"begin":54,"end":56},"obj":"Chemical"},{"id":"T171","span":{"begin":117,"end":119},"obj":"Chemical"}],"attributes":[{"id":"A168","pred":"chebi_id","subj":"T168","obj":"http://purl.obolibrary.org/obo/CHEBI_74756"},{"id":"A169","pred":"chebi_id","subj":"T169","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A170","pred":"chebi_id","subj":"T170","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A171","pred":"chebi_id","subj":"T171","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A172","pred":"chebi_id","subj":"T171","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"}],"text":"Anti-PD-1 (pembrolizumab) + tocilizumab NCT04335305 II Nanjing, China 24 Pneumatic COVID19+ Tocilizumab = anti-IL-6R"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1206","span":{"begin":5,"end":9},"obj":"Gene"},{"id":"1207","span":{"begin":117,"end":122},"obj":"Gene"},{"id":"1238","span":{"begin":78,"end":95},"obj":"Disease"}],"attributes":[{"id":"A1206","pred":"tao:has_database_id","subj":"1206","obj":"Gene:5133"},{"id":"A1207","pred":"tao:has_database_id","subj":"1207","obj":"Gene:3570"},{"id":"A1238","pred":"tao:has_database_id","subj":"1238","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Anti-PD-1 (pembrolizumab) + tocilizumab NCT04335305 II Nanjing, China 24 Pneumatic COVID19+ Tocilizumab = anti-IL-6R"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T131","span":{"begin":117,"end":122},"obj":"http://purl.obolibrary.org/obo/GO_0004915"}],"text":"Anti-PD-1 (pembrolizumab) + tocilizumab NCT04335305 II Nanjing, China 24 Pneumatic COVID19+ Tocilizumab = anti-IL-6R"}

{"project":"LitCovid-sentences","denotations":[{"id":"T238","span":{"begin":0,"end":122},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Anti-PD-1 (pembrolizumab) + tocilizumab NCT04335305 II Nanjing, China 24 Pneumatic COVID19+ Tocilizumab = anti-IL-6R"}